Cantitate/Preț
Produs

Pioneers of Immuno-Oncology

Autor Neil Canavan
en Limba Engleză Hardback – 30 oct 2017
The way we treat cancer is about to change forever. This revolutionand it is precisely thatwas sparked not by the invention of a new drug, but by the evolution of an entirely new way of thinking about and managing cancer. Going forward, doctors will not use pharmaceuticals to attack tumors not directly. Rather, the oncologist will treat the patient's immune system with a drug, and then the patient will treat the tumor.
Based entirely on interviews with the investigators, this book is the story of the IO pioneers. It's a story of failure, resurrection, and success. It's a story about science, it's a story about discovery, and intuition, and cunning. It's a peek into the lives and thoughts of some of the most gifted medical scientists on the planet.
This is not a textbook. This is a life book. This technology will save/is saving lives, and the book will celebrate the living, breathing, thinking, charming, arrogant, funny, obstinate, drinking-too-much, not-drinking-enough, amazing human beings who are making IO happen.
Citește tot Restrânge

Preț: 16041 lei

Nou

Puncte Express: 241

Preț estimativ în valută:
3071 3192$ 2546£

Carte disponibilă

Livrare economică 15-29 ianuarie 25

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9781621822172
ISBN-10: 1621822176
Pagini: 250
Dimensiuni: 237 x 161 x 27 mm
Greutate: 0.68 kg
Editura: Cold Spring Harbor Laboratory Press

Notă biografică

Neil Canavan is a veteran journalist specializing in science and medicine, a career he embarked upon after earning a master's degree in molecular and cellular biodynamics from Rutgers University. With more than 15 years of reporting experience, and some 200 feature articles to his credit Neil has written for such news outlets as WebMD, Medscape, Drug Discovery and Development Magazine, and The Scientist. Currently, Neil is a contributing editor to The Oncology Business Review where he has written many articles on the technology of, and clinical outcomes for cancer immunotherapy.

Since 2014 Neil has held the position of Scientific Advisor at The Trout Group, a New York-based investor relations firm focused on healthcare biotechnology. The Trout Group has 30 clients in the oncology space, with many of those companies pursuing the development of cancer immunotherapies.